KRAS and non-small cell lung carcinoma: Sotorasib was the first approved by the FDA as a second-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with confirmed KRAS G12C mutations, following the success of the CodeBREAK100 trial, as well as many other CodeBREAK trials (NCT03600883) (Liu et al., 2023).